Abstracts tagged "Antiphospholipid antibodies"

Abstract Number: 14 • 2013 ACR/ARHP Annual Meeting
Isotype Dependent Performance Of Beta₂glycoprotein I Immunoassays In Two Diverse Patient Cohorts: Implications For Assay Harmonization and Standardization
Anne E. Tebo^1,2, Rohan Willis³, Troy Jaskowski⁴, Jane E. Salmon⁵, Michelle Petri⁶, Ware D. Branch^7,8 and Silvia S. Pierangeli³, ¹Pathology, University of Utah, Salt Lake City, UT, ²Medical Directorship, ARUP Laboratories, Salt Lake City, UT, ³Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ⁴ARUP Laboratories, Salt Lake City, UT, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Obsterics and Gynecology, Univ of Utah, Salt Lake City, UT, ⁸Intermountain Healthcare, Salt Lake City, UT
Background/Purpose: The presence IgG and/or IgM beta2 glycoprotein I (β2GPI) antibodies are associated with thrombosis and/or pregnancy-related morbidity in antiphospholipid syndrome (APS) and/or systemic lupus…
Abstract Number: 18 • 2013 ACR/ARHP Annual Meeting
Clinical Correlates Of Positive Anti-Cardiolipin and β-2 Glycoprotein 1 Antibodies In a Cohort Of 110 Patients At Mayo Clinic
Uma Thanarajasingam¹, Cynthia S. Crowson², Melissa R. Snyder³, Rajeev Pruthi⁴, Harvinder S. Luthra⁵ and Kevin G. Moder⁶, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³2Division of Clinical Biochemistry and Immunology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, ⁴Divison of Hematology, Mayo Clinic, Rochester, MN, ⁵Medicine/Division of Rheum, Mayo Clinic, Rochester, MN, ⁶Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Testing for antiphospholipid antibodies is typically indicated for diagnosis and prognosis of antiphospholipid syndromes, however, selected patients undergo testing for other reasons. The clinical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].